Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Tourmaline Bio(TRML.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 51.6% and a total average return of 2.
Truist Financial Remains a Buy on Tourmaline Bio (TRML)
Tourmaline Bio Showcases Promising Candidate in Updated Presentation
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Piper Sandler analyst Yasmeen Rahimi maintains $Tourmaline Bio(TRML.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 37.3%
Tourmaline Bio (TRML) Receives a Buy From Piper Sandler
Tourmaline Bio to Present at Upcoming Investor Conferences